Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

A. Belldegrun, D. E. Webb, H. A. Austin, S. M. Steinberg, D. E. White, W. M. Linehan, S. A. Rosenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Adoptive transfer of autologous lymphokine-activated killer cells in conjunction with recombinant interleukin-2 in patients with advanced cancer has produced significant regression of metastatic disease in selected patients. We analyzed the effects of interleukin-2 regimens on renal function in 99 consecutive patients. Interleukin-2 therapy with or without lymphokine-activated killer cells was associated with varying degrees of hypotension, fluid retention, azotemia, oliguria, and low fractional sodium excretion. After the patients completed the interleukin-2 regimens, their renal function improved promptly. Renal function values returned to baseline levels within 7 days in 62% of patients, within 14 days in 84%, and within 30 days in 95%. Pretherapy serum creatinine values above 1.4 mg/dL predicted the severity of azotemia and prolonged duration of renal functional recovery. Interleukin-2 therapeutic regimens induce prerenal azotemia. Careful selection of patients and early detection of adverse physiologic changes may alleviate the side effects of interleukin-2 therapy.

Original languageEnglish (US)
Pages (from-to)817-822
Number of pages6
JournalAnnals of internal medicine
Volume106
Issue number6
DOIs
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer'. Together they form a unique fingerprint.

Cite this